Patents by Inventor David Mark Parry

David Mark Parry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-pyrimidineamine derivatives and processes for their preparation
    Patent number: 6552029
    Abstract: Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R2 is a hydrogen or halogen atom or a group —X1—R2a where X1 is a direct bond or a linker atom or group, and R2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: April 22, 2003
    Assignee: Celltech R&D Limited
    Inventors: Peter David Davis, David Festus Charles Moffat, Mark James Batchelor, Martin Clive Hutchings, David Mark Parry
  • 2-Pyrimidineamine derivatives and processes for their preparation
    Patent number: 6114333
    Abstract: Compounds of general formula (1) ##STR1## are described wherein: Ar is an optionally substituted aromatic group;R.sup.2 is a hydrogen or halogen atom or a group --X.sup.1 --R.sup.2a where X.sup.1 is a direct bond or a linker atom or group, and R.sup.2a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;R.sup.3 is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof.The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: September 5, 2000
    Assignee: Celltech Therapeutics Ltd.
    Inventors: Peter David Davis, David Festus Charles Moffat, Mark James Batchelor, Martin Clive Hutchings, David Mark Parry